Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)(TAK)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$15.76
52-Week Range
$12.99 – $18.89
YTD
+0.89%
IV Rank (30D)
81.46
Straddle Price
$1.42
P/C Vol Ratio
0.46
Market Cap
$49.3B
Fair Value
-50.0% vs price
Confidence: 13% Alpha Score: 0.40

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.49%
Beta vs SPY1.00
Cost of Equity (CAPM)9.99% (VRP-adj)
WACC9.97%
Volatility Risk Premium+100.8pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$16.93 (Market Anchor value)
SMA 20 / Bollinger Mid$16.11
Bollinger Width / SMA2081.9% (drives anchor stability)
Net Debt$0.0B
Peers used for multiples: ABBV, BMY, LLY, MRK, NVO, NVS, PFE, SNY
Blended Fair Value
$4.75
Current Price
$15.74
Deviation
-50.0%
Forward-Return Rank SHORT gated
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -1.5% +0.68 -1.26 3.9%
42d -2.5% +0.64 -1.26 3.9%
63d -3.8% +0.23 -1.26 3.9%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) $4.75 100%
Peer P/E n/a 0% median 36.5× · 6 peers
Peer EV/EBITDA n/a 0% median 16.9× · 6 peers
Peer P/B n/a 0% median 5.8× · 5 peers
Peer P/S n/a 0% median 5.4× · 6 peers
Market Anchor (SMA50) $16.93 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-08 · updated 2026-06-08 21:00:06.594000
Info
Exchange
XNYS
Market Cap
$49.3B

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +3.50% 6
Feb +2.50% 6
Mar -0.48% 6
Apr -2.90% 6
May -0.34% 6
Jun +0.22% 6
Jul +0.25% 5
Aug +2.09% 5
Sep -2.87% 5
Oct -6.62% 5
Nov +2.39% 5
Dec +2.68% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $16.08
SMA 50: $16.89
SMA 200: $15.99
Current: $15.74
EMA 12: $15.75
EMA 26: $16.14
MACD: -0.3948 | Signal: -0.0172
BEARISH
ADX (14): 36.34
TREND
+DI: 25.33
−DI: 39.70
Momentum Oscillators
RSI (14): 41.39
NEUTRAL
Stoch %K: 39.97
Stoch %D: 27.79
Williams %R: -52.38
Volume & Volatility
BB Upper: $17.14
BB Lower: $15.01
NEUTRAL
OBV: 82,053,914
Vol SMA 20: 3,385,856
Vol ROC: -1.92%
ATR: $0.31
True Range: $0.26
HV 20: 25.7%
HV 30: 23.1%
HV 60: 23.0%

Data Summary
Data Points: 500
Last Updated: 2026-06-08T21:15:09.636000
Date Range: 2024-06-10T00:00:00 – 2026-06-08T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Options Activity
IV Rank (30D)
81.46
IV Rank (7D)
100
Avg IV
139.9%
Straddle (30D)
$1.42
Straddle (7D)
$1.38
P/C Volume
0.46
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.37
Correlation (SPY)
21.7%
0.05
Ann. Volatility
20.5%
SPY Volatility
12.1%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

367 filers98,174,331 shares$1.73B value
# Filer Shares Value % of Total % of Float Period
1 Capital Research Global Investors 19,104,219 $353.81M 20.44% 2026-03-31
2 FMR LLC Custodian 7,117,486 $131.82M 7.62% 2026-03-31
3 ADAGE CAPITAL PARTNERS GP, L.L.C. 6,424,984 $118.99M 6.88% 2026-03-31
4 GOLDMAN SACHS GROUP INC Custodian 5,618,728 $104.06M 6.01% 2026-03-31
5 MORGAN STANLEY Custodian 6,373,202 $99.36M 5.74% 2025-12-31
6 BRANDES INVESTMENT PARTNERS, LP 4,430,642 $82.06M 4.74% 2026-03-31
7 BlackRock, Inc. Custodian 3,176,421 $58.83M 3.40% 2026-03-31
8 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 3,116,311 $57.71M 3.33% 2026-03-31
9 RENAISSANCE TECHNOLOGIES LLC 2,989,100 $55.36M 3.20% 2026-03-31
10 UBS Group AG Custodian 2,740,229 $50.75M 2.93% 2026-03-31
11 D. E. Shaw & Co., Inc. Custodian 2,602,543 $48.20M 2.79% 2026-03-31
12 FIRST TRUST ADVISORS LP 1,971,074 $36.50M 2.11% 2026-03-31
13 NORTHERN TRUST CORP Custodian 1,961,038 $36.32M 2.10% 2026-03-31
14 MANAGED ASSET PORTFOLIOS, LLC 1,798,398 $33.31M 1.92% 2026-03-31
15 ENVESTNET ASSET MANAGEMENT INC 1,411,927 $26.15M 1.51% 2026-03-31
16 Quantinno Capital Management LP 1,289,326 $23.88M 1.38% 2026-03-31
17 WELLS FARGO & COMPANY/MN Custodian 1,136,022 $21.04M 1.22% 2026-03-31
18 AQR CAPITAL MANAGEMENT LLC Custodian 894,423 $16.56M 0.96% 2026-03-31
19 Capital Wealth Planning, LLC 886,835 $16.42M 0.95% 2026-03-31
20 STIFEL FINANCIAL CORP Custodian 628,550 $11.64M 0.67% 2026-03-31
21 Crossmark Global Holdings, Inc. 745,176 $11.62M 0.67% 2025-12-31
22 CITADEL ADVISORS LLC Custodian 624,160 $11.56M 0.67% 2026-03-31
23 ROYAL BANK OF CANADA Custodian 614,851 $11.39M 0.66% 2026-03-31
24 Creative Planning 542,996 $10.06M 0.58% 2026-03-31
25 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 540,348 $10.01M 0.58% 2026-03-31
4 filers$30.23M notional
# Filer Notional Value % of Total Period
1 CITADEL ADVISORS LLC Custodian $27.96M 92.47% 2026-03-31
2 Walleye Trading LLC $1.79M 5.91% 2026-03-31
3 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $411.14K 1.36% 2026-03-31
4 Walleye Capital LLC $81.49K 0.27% 2026-03-31
2 filers$1.36M notional
# Filer Notional Value % of Total Period
1 Walleye Trading LLC $750.06K 55.25% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $607.46K 44.75% 2026-03-31
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.